No Detail Found!

Investigating the anti-angiogenic effects of Fufang Kushen Injection in combination with cisplatin using a zebrafish model

Author(s)
Liwen Han Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, Shandong, China; Biology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan, China
Wenxian Zhang Department of TCM Orthopedics & Traumatology, Gansu province hospital of TCM,Lanzhou,China
Xiaobin Li Biology Institute, Qilu University of Technology (Shandong Academy of Sciences),Jinan,China
Qiuxia He Biology Institute, Qilu University of Technology (Shandong Academy of Sciences),Jinan,China
Jian Han Biology Institute, Qilu University of Technology (Shandong Academy of Sciences),Jinan,China
Yun Zhang Biology Institute, Qilu University of Technology (Shandong Academy of Sciences),Jinan,China
Chen Sun Biology Institute, Qilu University of Technology (Shandong Academy of Sciences),Jinan,China
Hong Zhou Department of TCM Orthopedics & Traumatology, Gansu province hospital of TCM,Lanzhou,China
Kechun Liu Biology Institute, Qilu University of Technology (Shandong Academy of Sciences),Jinan,China
Abstract
The Traditional Chinese Medicine formula Fufang Kushen Injection (FKI) has demonstrated potential to enhance the efficacy and reduce the toxicity of the chemotherapeutic drug cisplatin. However, there is insufficient evidence to determine whether the combination of matrine and cisplatin were linked to the angiogenesis pathway. In this study, we selected two zebrafish lines, AB and Tg (vegfr2: GFP), as in vivo models to rapidly assess the antiangiogenesis effects. KFI and cisplatin had no obvious effects when used individually, but combined KFI (5 and 10 µL/mL) and cisplatin (50µg/mL) significantly inhibited the zebrafish intersegmental vessel (ISV) formation and growth. Matrine at 50 µg/mL also showed synergetic anti-angiogenesis activity with cisplatin (50µg/mL) in 48hpf zebrafish larvae. This study has shown the potential of FKI to enhance cisplatin efficacy and reduce its toxicity by inhibiting angiogenesis. These results contribute to the scientific evidence supporting the use of KFI in combination with cisplatin to treat cancer in the clinic.
Publication Details
Page(s) 1955-1960
DOI DOI not available
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 33, Issue: 5, Year: 2020

Request the full text from PASTIC

Keywords
Cisplatin, angiogenesis, Fufang Kushen Injection (FKI), Zebrafish
0

Citations

0

Downloads

87

Views